Drug Trial Radar · NCT07790640
Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
351
Actual
Start
Aug 11, 2025
Primary completion
Apr 1, 2027
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Taejoon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to evaluate the superiority of the myopia progression control effect in the treatment group compared with the control group, evaluated by the change in spherical equivalent (SE) after 12 months of administration of the investigational product.
Conditions
- Myopia
Interventions
CTO0308Drug
Ophthalmic solution, one drop in each eye, once daily
Vehicle (Placebo solution)Drug
Vehicle, one drop in each eye, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Spherical Equivalent (SE)Time frame: Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gachon University Gil Medical Center
Incheon, Incheon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.